Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 3
1998 3
1999 4
2000 1
2001 1
2002 2
2003 1
2005 2
2006 1
2007 2
2008 1
2009 2
2010 7
2011 8
2012 5
2013 4
2014 3
2015 8
2016 8
2017 17
2018 13
2019 7
2020 18
2021 13
2022 12
Text availability
Article attribute
Article type
Publication date

Search Results

123 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Hernández-Martín I, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Posso M, Rocha C, Quirce S, Sastre J, Shamji M, Song Y, Steiner C, Schwarze J, Alonso-Coello P, Palomares O, Jutel M. Agache I, et al. Among authors: perez de llano l. Allergy. 2020 May;75(5):1023-1042. doi: 10.1111/all.14221. Epub 2020 Feb 24. Allergy. 2020. PMID: 32034960
EAACI Biologicals Guidelines-Recommendations for severe asthma.
Agache I, Akdis CA, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Chu DK, Del Giacco S, Eiwegger T, Flood B, Firinu D, Gern JE, Hamelmann E, Hanania N, Hernández-Martín I, Knibb R, Mäkelä M, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Pfaar O, Quirce S, Sastre J, Shamji M, Schwarze J, Palomares O, Jutel M. Agache I, et al. Among authors: perez de llano l. Allergy. 2021 Jan;76(1):14-44. doi: 10.1111/all.14425. Epub 2020 Aug 10. Allergy. 2021. PMID: 32484954
Asthma-COPD overlap: identification and optimal treatment.
Cosío BG, Dacal D, Pérez de Llano L. Cosío BG, et al. Among authors: perez de llano l. Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618805662. doi: 10.1177/1753466618805662. Ther Adv Respir Dis. 2018. PMID: 30336736 Free PMC article. Review.
Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort.
Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW, Christoff GC, Cosio BG, FitzGerald JM, Heffler E, Iwanaga T, Jackson DJ, Menzies-Gow AN, Papadopoulos NG, Papaioannou AI, Pfeffer PE, Popov TA, Porsbjerg CM, Rhee CK, Sadatsafavi M, Tohda Y, Wang E, Wechsler ME, Alacqua M, Altraja A, Bjermer L, Björnsdóttir US, Bourdin A, Brusselle GG, Buhl R, Costello RW, Hew M, Koh MS, Lehmann S, Lehtimäki L, Peters M, Taillé C, Taube C, Tran TN, Zangrilli J, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Hosseini N, Kerkhof M, Murray RB, Price CA, Price DB. Heaney LG, et al. Among authors: perez de llano l. Chest. 2021 Sep;160(3):814-830. doi: 10.1016/j.chest.2021.04.013. Epub 2021 Apr 19. Chest. 2021. PMID: 33887242 Free article.
Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry.
Denton E, Price DB, Tran TN, Canonica GW, Menzies-Gow A, FitzGerald JM, Sadatsafavi M, Perez de Llano L, Christoff G, Quinton A, Rhee CK, Brusselle G, Ulrik C, Lugogo N, Hore-Lacy F, Chaudhry I, Bulathsinhala L, Murray RB, Carter VA, Hew M. Denton E, et al. Among authors: perez de llano l. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2680-2688.e7. doi: 10.1016/j.jaip.2021.02.059. Epub 2021 Mar 18. J Allergy Clin Immunol Pract. 2021. PMID: 33744476 Free article.
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I, Rocha C, Beltran J, Song Y, Posso M, Solà I, Alonso-Coello P, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M. Agache I, et al. Among authors: perez de llano l. Allergy. 2020 May;75(5):1043-1057. doi: 10.1111/all.14235. Allergy. 2020. PMID: 32064642
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study.
Menzies-Gow AN, McBrien C, Unni B, Porsbjerg CM, Al-Ahmad M, Ambrose CS, Dahl Assing K, von Bülow A, Busby J, Cosio BG, FitzGerald JM, Garcia Gil E, Hansen S, aHeaney LG, Hew M, Jackson DJ, Kallieri M, Loukides S, Lugogo NL, Papaioannou AI, Larenas-Linnemann D, Moore WC, Perez-de-Llano LA, Rasmussen LM, Schmid JM, Siddiqui S, Alacqua M, Tran TN, Suppli Ulrik C, Upham JW, Wang E, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Murray RB, Price CA, Price DB. Menzies-Gow AN, et al. Among authors: perez de llano la. J Asthma Allergy. 2022 Jan 13;15:63-78. doi: 10.2147/JAA.S328653. eCollection 2022. J Asthma Allergy. 2022. PMID: 35046670 Free PMC article.
Distilling Fact from the Vapor of Nuance: Asthma Exacerbations.
Pérez de Llano L, Dacal-Rivas D, Blanco-Cid N, Martín-Robles I. Pérez de Llano L, et al. J Allergy Clin Immunol Pract. 2021 Feb;9(2):842-843. doi: 10.1016/j.jaip.2020.10.007. J Allergy Clin Immunol Pract. 2021. PMID: 33551042 No abstract available.
123 results